甘李药业股份有限公司关于变更保荐代表人的公告

Core Viewpoint - Gannee Pharmaceutical Co., Ltd. has announced a change in its sponsoring representative for its initial public offering (IPO) on the Shanghai Stock Exchange, with the new representative being Shao Caijie, replacing Wang Qi due to a job change [1][2]. Group 1 - The company received a notice from CITIC Securities regarding the change of sponsoring representative for its IPO project [1]. - Wang Qi is no longer responsible for the company's continuous supervision duties as of February 2026, leading to the appointment of Shao Caijie as the new sponsoring representative [2]. - The continuous supervision period will last until the obligations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange are fulfilled [2]. Group 2 - The company's board expressed gratitude for Wang Qi's contributions during his tenure as the sponsoring representative [3]. - Shao Caijie holds a master's degree and is currently the director of the Investment Banking Management Committee at CITIC Securities, with a strong track record in IPO projects [4].